Clinical Trial Update: Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring neoadjuvant moderately hypofractionated radiotherapy combined with chemotherapy and immunotherapy for high-risk locally advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Rectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING